Group 1 - Digital Zhengtong's subsidiary Baoding Jindi won a bid for a smart water project in Jinan, with a total contract value of 109 million yuan, of which Baoding Jindi's share is approximately 77 million yuan [1] - Lingzhi Software plans to acquire 100% equity of Kaimiride through a combination of cash and stock issuance, with the final transaction price yet to be determined [1] - Tianjin Port's subsidiary plans to transfer 60% equity of China Railway Storage and Transportation, with an estimated value of 37.54 million yuan for the entire equity [2] Group 2 - New Wufeng reported a 56.97% year-on-year increase in pig sales in October, selling 610,000 pigs [3] - New Peng Co. announced a joint investment of approximately 15 million USD with Jabil to build a battery storage box project in Thailand [4] - Maiwei Bio received approval for a clinical trial of its 9MW3811 injection for pathological scars [6] Group 3 - Jiangsu Sopo completed maintenance and resumed production of its methanol and acetic acid facilities [8] - Luoniushan reported a 24.65% year-on-year increase in pig sales revenue in October, totaling 116 million yuan [9][10] - Zhongbei Communication signed a 1 billion yuan comprehensive computing service framework agreement with Xiamen Hongxin Electronics [11] Group 4 - Huayang New Materials announced the resignation of its general manager, Wu Yuehua [12] - Zhongxin Co. used 50 million yuan of idle funds to purchase structured deposits with expected annual returns between 0.55% and 2.05% [14] - Huajian Group's subsidiary signed a construction engineering design contract worth 96.54 million yuan [16] Group 5 - Jianyou Co. received FDA approval for a new production site for its injectable drug [17] - Beilu Pharmaceutical obtained a drug registration certificate for its iodine mepivacaine injection, which is included in the national medical insurance catalog [19] - *ST Yuancheng's stock will be suspended due to falling below the market cap threshold for delisting [20] Group 6 - Xiantan Co. reported a 9.3% year-on-year increase in chicken product sales revenue in October, totaling 503 million yuan [21] - Huanxu Electronics reported an 8.93% year-on-year decrease in consolidated revenue for October, amounting to 5.598 billion yuan [23] - Yisheng Co. reported a 22.97% year-on-year decrease in white feather chicken seed sales revenue in October [25] Group 7 - Yuandong Bio initiated a Phase I/II clinical trial for its ADC drug YLSH003 targeting advanced solid tumors [25] - Xiaoming Co. reported a 34.89% year-on-year decrease in chicken product sales revenue in October [26] - Nanjiao Food reported a 5.27% year-on-year decrease in consolidated revenue for October, totaling 235 million yuan [28] Group 8 - Chuangye Huikang announced a potential change in control, leading to a temporary stock suspension [30] - Tangrenshen reported a 17.91% year-on-year decrease in pig sales revenue in October, totaling 828 million yuan [32][33] - Wancheng Group plans to distribute a cash dividend of 1.5 yuan per 10 shares to shareholders [34] Group 9 - Kangguan Technology plans to distribute a cash dividend of 3.6 yuan per 10 shares to shareholders [36] - Shoudu Online's executive plans to reduce holdings of up to 19,400 shares [38] - Maolai Optical received approval for the issuance of convertible bonds [40] Group 10 - Jinkai New Energy plans to distribute a cash dividend of 0.1 yuan per share to shareholders [41] - Tianchen Medical raised the upper limit for share repurchase to 70 yuan per share [42] - Tianmu Lake used 38 million yuan of idle funds to purchase structured deposits [43]

Group 1 - The company Chuangyue Huikang announced that its largest shareholder, Mr. Ge Hang, who holds more than 5% of the shares, is planning control-related matters with Hangzhou Genghao Zhito Management Consulting Partnership (Limited Partnership) [2] - This matter may lead to a change in the company's status from having no actual controller to having an actual controller [2] - The company has applied to the Shenzhen Stock Exchange for a trading suspension, effective from November 10, 2025, with an expected suspension period of no more than 2 trading days [2] Group 2 - The final implementation and results of this transaction remain uncertain [2] - Investors are advised to pay attention to subsequent announcements and be aware of investment risks [2]

Group 1 - The largest shareholder of Chuangye Huikang, Ge Hang, is planning to change the company's status from having no actual controller to having one, which may impact control over the company [1] - Chuangye Huikang's stock was suspended from trading starting November 10, 2025, with an expected suspension period of no more than two trading days [1] - Prior to the suspension, the stock price surged by 7% on November 7, 2025, closing at 5.18 yuan per share with a trading volume of 674 million yuan [3] Group 2 - Chuangye Huikang has been experiencing financial difficulties, reporting a revenue of 1.423 billion yuan in 2024, a year-on-year decrease of 11.96%, and a net loss of 174 million yuan, also a decline of 11.96% [3] - For the first three quarters of 2025, the company reported a revenue of 862 million yuan, down 26.26% year-on-year, and a net loss of 122 million yuan, with a significant decline of 331.69% [3] - The company faced a quarterly loss of 41.67 million yuan in Q3 2025, with revenue dropping by 35.5% year-on-year [3] Group 3 - Multiple major shareholders have been reducing their stakes in Chuangye Huikang, with Ge Hang planning to sell up to 37.038 million shares between October 23, 2025, and January 22, 2026, representing approximately 2.40% of the total share capital [3] - Ge Hang previously reduced his holdings by 9.2947 million shares from July to September 2025, accounting for 0.6018% of the shares [4] - Philips, the second-largest shareholder, also announced plans to reduce its stake by up to 46.3328 million shares from August 27 to November 26, 2025, which is about 3% of the total share capital [4]

Core Points - The company, Chuangye Huikang, announced that its largest shareholder, Ge Hang, who holds over 5% of the shares, is in discussions with Hangzhou Genghao Zhito Management Consulting Partnership regarding control-related matters [1] - This potential change may result in the company transitioning from having no actual controller to having one [1] - As a result of this announcement, the company has applied to the Shenzhen Stock Exchange for a trading suspension, effective from November 10, 2025, with an expected duration of no more than 2 days [1]

每经AI快讯，创业慧康（300451）11月10日公告，公司第一大股东、持股5%以上股东葛航正与杭州更 好智投管理咨询合伙企业(有限合伙)筹划控制权相关事宜，该事项可能导致公司将由无实际控制人状态 变更为有实际控制人状态。经公司向深圳证券交易所申请，公司股票自2025年11月10日(星期一)开市起 停牌，预计停牌时间不超过2个交易日。 ...

北京商报讯（记者 丁宁）11月10日午间，华检医疗（01931.HK）在港交所公告称，公司下属企业出资 设立的有限合伙企业杭州更好智投管理咨询合伙企业（有限合伙），目前正在与创业慧康第一大股东葛 航筹划创业慧康控制权相关事宜。 华检医疗表示，截至公告日期，各方主体仍就可能交易的具体方案（包括但不限于交易结构、代价、时 间表及先决条件）进行论证和磋商。可能交易的最终条款须待相关方进一步谈判并签订正式协议后方可 作实。 ...

Core Viewpoint - Huajian Medical (01931) is in discussions regarding a potential control transaction involving Chuangye Huikang Technology Co., Ltd. (Chuangye Huikang) and its largest shareholder, Ge Hang [1] Group 1: Company Information - Huajian Medical has established a limited partnership enterprise in China, named Hangzhou Genghao Zhito Management Consulting Partnership (Limited Partnership), funded by its subsidiary [1] - Chuangye Huikang is a joint-stock company registered in China, listed on the Shenzhen Stock Exchange's ChiNext board [1] Group 2: Transaction Details - As of the date of the announcement, all parties are still discussing the specific terms of the potential transaction, including but not limited to transaction structure, cost, timeline, and preconditions [1] - The final terms of the potential transaction will require further negotiations and the signing of a formal agreement among the relevant parties [1]

华检医疗(01931)发布公告，公司一家于中国境内设立的有限合伙企业，杭州更好智投管理咨询合伙企 业(有限合伙)(该企业由公司下属企业出资设立，并依照中国法律组建及存续)，目前正在与创业慧康 （300451）科技股份有限公司(创业慧康)第一大股东葛航先生筹划创业慧康控制权相关事宜(可能交 易)。创业慧康(股份代号：300451.SZ)为一间于中国注册成立的股份有限公司，其股份于深圳证券交易 所创业板上市。 截至本公告日期，各方主体仍就可能交易的具体方案(包括但不限于交易结构、代价、时间表及先决条 件)进行论证和磋商。可能交易的最终条款须待相关方进一步谈判并签订正式协议后方可作实。 ...

截至公告日期，各方主体仍就可能交易的具体方案(包括但不限于交易结构、代价、时间表及先决条件) 进行论证和磋商。可能交易的最终条款须待相关方进一步谈判并签订正式协议后方可作实。 格隆汇11月10日丨华检医疗(01931.HK)公布，公司一家于中国境内设立的有限合伙企业，杭州更好智投 管理谘询合伙企业(有限合伙)(该企业由公司下属企业出资设立，并依照中国法律组建及存续)，目前正 在与创业慧康科技股份有限公司("创业慧康")第一大股东葛航筹划创业慧康控制权相关事宜。创业慧康 (股份代号：300451.SZ)为一间于中国注册成立的股份有限公司，其股份于深圳证券交易所创业板上 市。 ...

格隆汇11月10日丨华检医疗(01931.HK)公布，公司一家于中国境内设立的有限合伙企业，杭州更好智投 管理谘询合伙企业(有限合伙)(该企业由公司下属企业出资设立，并依照中国法律组建及存续)，目前正 在与创业慧康科技股份有限公司("创业慧康")第一大股东葛航筹划创业慧康控制权相关事宜。创业慧康 (股份代号：300451.SZ)为一间于中国注册成立的股份有限公司，其股份于深圳证券交易所创业板上 市。 截至公告日期，各方主体仍就可能交易的具体方案(包括但不限于交易结构、代价、时间表及先决条件) 进行论证和磋商。可能交易的最终条款须待相关方进一步谈判并签订正式协议后方可作实。 ...